Carregando...
Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue
Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency. Phosphodiesterase type 5 inhibitors (PDE5i) have...
Na minha lista:
| Publicado no: | Int J Endocrinol |
|---|---|
| Principais autores: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7407035/ https://ncbi.nlm.nih.gov/pubmed/32774364 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/7078108 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|